With two decades of expertise, ETAP-Lab stands as a recognized leader in preclinical dermatology. Leveraging our gold standard models and tailor-made solutions, we address your challenges in molecule development, spanning across areas such as psoriasis, atopic dermatitis, wound healing, skin grafting, and more.
Since its inception, ETAP-Lab has showcased robust consistently expertise in preclinical neurology, initially focusing on in vivo models and more recently expanding into in vitro approaches. We specialize particularly such as stroke, neurodegenerative diseases featuring Alzheimer’s and Parkinson’s models, as well as psychopharmacology and cognition.
With the recent acquisition of SYNCROSOME, ETAP-Lab significantly bolsters its expertise in cardiovascular pathologies. Dedicated to in-depth studies of major cardiovascular diseases, including Pulmonary Arterial Hypertension, Ischemia Reperfusion, and Heart failure, our team of experts conducts in vivo pharmacology studies.
ETAP-Lab has cultivated expertise in addressing a spectrum of gastrointestinal disorders, including irritable bowel syndrome (IBS) and traveler’s diarrhea. Our research extends to metabolic disturbances such as diabetes, obesity, and malnutrition induced by high-fat diets. Furthermore, ETAP-Lab is committed to conducting regulatory food toxicology studies in alignment with OECD standards.
About us
ETAP-Lab is an independent Contract Research Organization (CRO)
ETAP-Lab provides preclinical pharmacology and research services, as well as scientific expertise, to Pharmaceutical and Agro-Food industries. Our activity focuses on In Vivo models of pathologies and toxicology studies in rodents to support drug and nutraceutic R&D for our sponsors.
Since the foundation in 1991, ETAP-Lab’s Scientists have an in-depth expertise in pathology modeling with rodents. By respecting rodent chronobiology and natural behaviors, ETAP-Lab proposes research models with added translational value. All our models are customizable and original specific models can be set-up and validated on request.
Subscribe to our newsletter
Our News
-
ETAP-Lab announces the acquisition of SYNCROSOME
ETAP-Lab announces the acquisition of SYNCROSOME, a CRO specialising in preclinical in vivo pharmacology services focused on cardiovascular pathologies. 🚀 This represents a significant step forward in the implementation of
-
BRYOFLAM : Maladies Inflammatoires et Neuro-Inflammatoires – L’espoir rĂ©side dans les mousses !
ETAP-Lab est fier de lancer officiellement le projet BRYOFLAM ! En collaboration avec Plant Advanced Technologies PAT et le laboratoire IMoPA-CNRS de l'Université de Lorraine, nous visons à découvrir de
-
Lancement lorrain de BIO-DIAMOND réussi sous le soleil de Nancy !
Hier, nous avons présenté avec notre partenaire NETRI le projet BIO-DIAMOND à notre écosystème local. Nous avons eu l'honneur d'accueillir Monsieur Christophe Choserot, président de Grand Nancy Innovation , Monsieur François Werner, vice-président de